CTOs on the Move

Affinium Pharmaceuticals

www.afnm.com

 
Affinium Pharmaceuticals , Inc. is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million
  • www.afnm.com
  • 100 University Ave
    Toronto, ON CAN M5J 1V6
  • Phone: 416.645.6600

Executives

Name Title Contact Details

Similar Companies

Psychiatric Medical Care

Through the use of telepsychiatry technology, we’re able to help our partner facilities see patients more efficiently and in a wide variety of locations.

The Harvard Drug Group

The Harvard Drug Group is a Livonia, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Servier Pharmaceuticals

Servier is a privately held international pharmaceutical company headquartered in France with a passion for innovation that has improved patients` lives around the world. With $4.7 billion in annual sales Servier operates in almost 150 countries worldwide across five therapeutic categories including oncology, cardiovascular, immuno-inflammatory, neuroscience and diabetes.

Insys

Insys Therapeutics is a commercial-stage specialty pharmaceutical company that develops and commercializes innovative supportive care products. We have two marketed products, Subsys and Dronabinol SG Capsule, which leverage our sublingual spray drug delivery technology and dronabinol formulation and manufacturing capabilities, respectively. In March 2012, we launched Subsys, our proprietary sublingual fentanyl spray for breakthrough cancer pain, or BTCP, in opioid-tolerant patients. Our focus is on the discovery, development and commercialization of innovative products to address chemotherapy-induced nausea and vomiting (CINV), pain management and other central nervous system disorders.

Allegro Ophthalmics

With over 100 years of combined experience, the seasoned leadership team at Allegro Ophthalmics is dedicated to delivering and establishing Integrin Peptide Therapy TM as the next generation pharmaceutical category for the treatment of wet age-related macular degeneration, diabetic retinopathy and diabetic macular edema. The potential to liberate patients from legal blindness to a much improved quality of life sustained by self-sufficient functional vision propels and accelerates our efforts.